Tom 11, Nr 2 (2020)
WYBRANE PROBLEMY KLINICZNE
Opublikowany online: 2020-08-17
Wyświetlenia strony
1969
Wyświetlenia/pobrania artykułu
120
Interdyscyplinarne stanowisko w sprawie rozpoznawania i leczenia otyłości
Forum Zaburzeń Metabolicznych 2020;11(2):47-54.
Streszczenie
Brak
Referencje
- Kaplan LM, Golden A, Jinnett K, et al. Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study. Obesity (Silver Spring). 2018; 26(1): 61–69.
- Raport NFZ „Cukier, otyłość – konsekwencje” z dnia 21.02.2019. https://www.nfz.gov.pl/aktualnosci/aktualnosci-centrali/prezentacja-raportu-cukier-otylosc-konsekwencje,7296.html (12.05.2020).
- WHO Global Strategy on Diet, Physical Activity and Health, 2020. https://www.who.int/dietphysicalactivity/childhood_what/en/ (12.05.2020).
- Edukacja Żywieniowa i Aktywność Fizyczna, 2019. https://www.ezaf.pl/wpisy/22-maja-europejski-dzien-walki-z-otyloscia,1451 (12.05.2020).
- Zasady postępowania w nadwadze i otyłości w praktyce lekarza rodzinnego. Wytyczne Kolegium Lekarzy Rodzinnych w Polsce, Polskiego Towarzystwa Medycyny Rodzinnej oraz Polskiego Towarzystwa Badań nad Otyłością̨. LEKARZ RODZINNY – WYDANIE SPECJALNE 3/2017. https://mlodzilekarzerodzinni.pl/wp-content/uploads/2020/01/Zasadypost%C4%99powaniawnadwadzeioty%C5%82o%C5%9Bci2018-1.pdf (12.05.2020).
- Tsigos C, Hainer V, Basdevant A, et al. Obesity Management Task Force of the European Association for the Study of Obesity. Management of obesity in adults: European clinical practice guidelines. Obes Facts. 2008; 1(2): 106–116.
- Li Z, Maglione M, Tu W. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005; 142(7): 532–546.
- Glandt M, Raz I. Present and future: pharmacologic treatment of obesity. J Obes. 2011; 2011: 636181.
- Nissen SE, Wolski KE, Prcela L, et al. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016; 315(10): 990–1004.
- Apovian CM, Aronne L, Rubino D, et al. COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013; 21(5): 935–943.
- SmPC Saxenda 6 mg/ml solution for injection in pre-filled pen. https://www.medicines.org.uk/emc/medicine/32753 (12.05.2020).
- Jendle J, Nauck MA, Matthews DR, et al. LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009; 11(12): 1163–1172.
- Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; 19(9): 1242–1251.
- Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012; 97(2): 258–266.
- Farr OM, Sofopoulos M, Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016; 59(5): 954–965.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373(1): 11–22.
- le Roux C, Astrup A, Fujioka K. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017; 389(10077): 1399–1409.
- Davies MJ, Bergenstal R, Bode B, et al. NN8022-1922 Study Group. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015; 314(7): 687–699.
- Blackman A, Foster GD, Zammit G. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) . 2016; 40(8): 1310–1319.
- Davies MJ, Aronne LJ, Caterson ID. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2014; 20(3): 734–739.
